About Us
Senya Therapeutics is pioneering an anti-leucine-rich α-2 glycoprotein 1 (LRG1) therapeutic platform to address major unmet clinical needs in nephrology, oncology, pulmonary disease and ophthalmology. Targeting LRG1 represents a new paradigm in the treatment of chronic disease.
Senya Therapeutics was founded in 2023 as a spin-out from University College London, UK building on inherited data accumulated over 15 years of world-leading research and know-how, which has translated into an extensive portfolio of patents related to therapeutic targeting of LRG1 enabling our first-in-class – best-in-class position.
About us
What we do
Our Science
Senya Therapeutics is pioneering an anti-leucine-rich α-2 glycoprotein 1 (LRG1) therapeutic platform
Learn more
Our Partners
We work with leading academic institutions and technology firms around the world
Learn more
The Team
Our team consists of pioneers of LRG1 science and experienced senior biotech executives. We collaborate with world class academic institutions in the UK, Europe, US and Asia that are conducting cutting-edge research on LRG1 therapeutics.
Learn more
Takashi Takenoshita
CEO
Dr. Chris Martin
Non-Executive Director
Professor John Greenwood
Co-founder, Co-CSO
Professor Emeritus Steve Moss
Co-founder, Co-CSO
Our pipeline
To our lead asset a pipeline of new anti-LRG1 biologics is being developed that will maintain our place at the forefront of LRG1 targeted therapy. The Company is led by a highly experienced Management Team, Board of Directors and Scientific Advisory Board comprising renowned international key opinion leaders.
News and Updates
View all news
Senya and Imperial College London Collaborate on Chronic Kidney Disease Research
Learn more
